Follow
Theresa Goletz
Theresa Goletz
Theresa Goletz Consulting LLC
No verified email
Title
Cited by
Year
Survey outcome on immunogenicity risk assessment tools for biotherapeutics: an insight into consensus on methods, application, and utility in drug development
J Gokemeijer, Y Wen, V Jawa, S Mitra-Kaushik, S Chung, A Goggins, ...
The AAPS Journal 25 (4), 55, 2023
52023
Anti-drug antibody validation testing and reporting harmonization
H Myler, J Pedras-Vasconcelos, K Phillips, CS Hottenstein, ...
The AAPS Journal 24, 1-23, 2022
302022
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
MK Joubert, M Deshpande, J Yang, H Reynolds, C Bryson, M Fogg, ...
PloS one 11 (8), e0159328, 2016
1102016
Preclinical development of AMG 139, a human antibody specifically targeting IL‐23
K Köck, WJ Pan, JM Gow, MJ Horner, JP Gibbs, A Colbert, TJ Goletz, ...
British Journal of Pharmacology 172 (1), 159-172, 2015
302015
Toll like receptor 3 antagonists, methods and uses
JM Carton, S Chen, M Cunningham, A Das, K Duffy, J Giles-Komar, ...
US Patent App. 13/799,476, 2014
2014
Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics
V Bi, V Jawa, MK Joubert, A Kaliyaperumal, C Eakin, K Richmond, O Pan, ...
Journal of pharmaceutical sciences 102 (10), 3545-3555, 2013
562013
A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies
TE Barger, D Wrona, TJ Goletz, DT Mytych
Nephrology Dialysis Transplantation 27 (10), 3892-3899, 2012
242012
The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective
JS Bee, TJ Goletz, JA Ragheb
Journal of pharmaceutical sciences 101 (10), 3580-3585, 2012
592012
Toll like receptor 3 antagonists, methods and uses
J Carton, RT Sarisky, N Stowell, R Sweet, S Zhao, S Chen, J Giles-Komar, ...
EP Patent App. 12,155,464 A, 2012
22012
Toll Like Receptor 3 Antagonists, Methods and Uses
JM Carton, S Chen, M Cunningham, A Das, K Duffy, JM Giles-Komar, ...
US Patent App. 13/412,259, 2012
92012
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses
MK Joubert, M Hokom, C Eakin, L Zhou, M Deshpande, MP Baker, ...
Journal of Biological Chemistry 287 (30), 25266-25279, 2012
2962012
Toll like receptor 3 antagonists, methods and uses
JM Carton, S Chen, M Cunningham, A Das, K Duffy, JM Giles-Komar, ...
US Patent 8,153,583, 2012
502012
232-P Validation of a cytometric bead array (CBA) assay to detect anti-erythropoiesis stimulating agent (ESA) antibodies to support diagnostic testing and pharmacovigilance
K Davis, T Barger, D Mytych, S Swanson, T Goletz, D Wrona
Human Immunology 1 (72), S161, 2011
2011
Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics
D Wullner, L Zhou, E Bramhall, A Kuck, TJ Goletz, S Swanson, ...
Clinical immunology 137 (1), 5-14, 2010
842010
antagonistas do receptor 3 semelhante a toll, mÉtodos e usos
J Carton, M Cunningham, D Anuk, K Duffy, TJ Goletz, DM Knight, R Lamb, ...
2008
Toll like receptor 3 antagonists, methods and uses toll 3
J Carton, M Cunningham, A Das, K Duffy, DM Knight, R Lamb, ML Mbow, ...
2008
Correlation of in silico prediction of immunogenicity of therapeutic proteins with immune responses in clinical studies.
V Jawa, D Mytych, M Moxness, D Zhong, S Swanson, N Chirmule, ...
The FASEB Journal 22, 563-563, 2008
2008
Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases
FF Shi, GR Gunn, LA Snyder, TJ Goletz
Vaccine 25 (17), 3338-3346, 2007
232007
Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
K Klimpel, TJ Goletz, N Arora, SH Leppla, JA Berzofsky
US Patent 7,097,965, 2006
122006
Toll like receptor 3 antagonists, methods and uses
J Carton, M Cunningham, A Das, K Duffy, DM Knight, R Lamb, ML Mbow, ...
2006
The system can't perform the operation now. Try again later.
Articles 1–20